Outcomes of target therapies for pediatric BRAF V600-mutant low-grade gliomas: A systematic review and meta-analysis
Neuro-Oncology Advances · 12.01.2026 · 8 (1)
DOI: 10.1093/noajnl/vdag192 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuro-Oncology Advances, online erschienen am 27.07.2026. Verfasst von Katherine Figueira und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Allied Health and Life Sciences, College of Health and Life Sciences, London South Bank University, London, UK (K.F., L.E.P.). Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This systematic review and meta-analysis evaluated the efficacy, safety, and available functional outcomes of targeted therapies, including BRAF and MEK inhibitors, in pediatric patients with BRAF V600-mutant low-grade gliomas (pLGGs). The review also explored their impact on clinical management, recovery, and quality of life.
Methods
The review followed PRISMA 2020 guidelines. Systematic searches were conducted across PubMed, ScienceDirect, EBSCO-hosted databases, and CENTRAL. Eligible studies included randomized controlled trials (RCTs) and retrospective studies (RS) reporting on tumor overall response rates (ORRs), progression-free survival (PFS), adverse events (AEs), and functional outcomes in patients aged 1-17 years. Risk of bias was assessed using CASP; the certainty of evidence was evaluated using the GRADE framework. Meta-analyses used a random-effects model (STATA 18.5). Funnel plots, Egger’s tests, and subgroup/sensitivity analyses explored bias and heterogeneity.
Results
Ten studies (16 treatment arms; 4 RCTs, 6 RS were included). Pooled ORR was 42.35% (95% CI, 29.41-55.29), and the median PFS was 23.03 months (95% CI, 17.18-28.88). Grade 3/4 AEs occurred in 30.56% (95% CI, 22.60-38.53), most commonly rash, fatigue, and fever. Subgroup analyses suggested higher efficacy and lower toxicity with BRAF inhibitors or combination therapy. Functional outcomes were inconsistently reported, though some evidence suggested improvements in vision and performance status.
Conclusions
Targeted therapies are effective and well tolerated in pediatric BRAF V600-mutant LGG, offering a promising alternative to chemotherapy, particularly in relapsed or progressive disease. Emerging evidence suggests potential benefit in selected molecularly defined patients; however, further prospective studies are required to define their role in first-line treatment. Standardized outcome reporting and long-term follow-up are essential to optimize care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Allied Health and Life Sciences, College of Health and Life Sciences, London South Bank University, London, UK (K.F., L.E.P.).
ORCID-Profile: Laura Elin Pigott
Zitieren
APA
Figueira, K., & Pigott, L. E. (2026). Outcomes of target therapies for pediatric BRAF V600-mutant low-grade gliomas: A systematic review and meta-analysis. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag192
Vancouver
Figueira K, Pigott LE. Outcomes of target therapies for pediatric BRAF V600-mutant low-grade gliomas: A systematic review and meta-analysis. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag192
BibTeX
@article{Figueira2026,
author = {Figueira, Katherine and Pigott, Laura Elin},
title = {Outcomes of target therapies for pediatric BRAF V600-mutant low-grade gliomas: A systematic review and meta-analysis},
journal = {Neuro-Oncology Advances},
year = {2026},
volume = {8},
number = {1},
doi = {10.1093/noajnl/vdag192}
}
EUVIMED